Portal de Periódicos da CAPES

BRAF Inhibitor Unveils Its Potential against Advanced Melanoma

2010; Cell Press; Volume: 18; Issue: 4 Linguagem: Inglês

10.1016/j.ccr.2010.10.001

1878-3686

Adina Vultur, Jessie Villanueva, Meenhard Herlyn,

Cutaneous Melanoma Detection and Management

Unresponsiveness to therapy is a hallmark feature of advanced metastatic melanoma. However, the discovery of BRAF-activating mutations in approximately 50% of human melanomas has provided an attractive therapeutic target. Here, we discuss two recent publications focusing on the mutant BRAF kinase inhibitor PLX4032 that validate oncogene-targeted melanoma therapy.